David R. Rahn & Associates Inc. Eli Lilly & CO Transaction History
David R. Rahn & Associates Inc.
- $324 Million
- Q1 2025
A detailed history of David R. Rahn & Associates Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, David R. Rahn & Associates Inc. holds 5,559 shares of LLY stock, worth $4.26 Million. This represents 1.42% of its overall portfolio holdings.
Number of Shares
5,559
Previous 5,212
6.66%
Holding current value
$4.26 Million
Previous $4.02 Million
14.12%
% of portfolio
1.42%
Previous 1.37%
Shares
6 transactions
Others Institutions Holding LLY
# of Institutions
4,393Shares Held
821MCall Options Held
10MPut Options Held
10.8M-
Pnc Financial Services Group, Inc. Pittsburgh, PA101MShares$77.6 Billion44.13% of portfolio
-
Lilly Endowment Inc Indianapolis, IN96MShares$73.5 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA79.2MShares$60.7 Billion1.22% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$50.4 Billion1.37% of portfolio
-
State Street Corp Boston, MA34.4MShares$26.4 Billion1.2% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $728B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...